ANGPTL3 and Combined hyperlipidemia: In a phase 1 trial, treatment of individuals with mixed hyperlipidemia with a monoclonal antibody targeting the angiopoietin-like protein 3/8 complex resulted in dose-dependent reductions in the levels of triglycerides and low-density lipoprotein cholesterol, while increasing the levels of high-density lipoprotein.